



Influenza Situation Report: 2015-2016 Season

Department of the Navy

Week 26 (26 June to 02 July 2016)

Overall Summary

Influenza activity is winding down. Laboratory, pharmacy and ILI indicators are at or below baseline. No cases of influenza were identified among children or in an inpatient setting.

Key Findings

Influenza Activity and Surveillance

Laboratory



Ten laboratory positive influenza cases were identified during Week 26, below baseline. [Details](#)

Antivirals (AVs)

Six AV prescriptions were dispensed in Week 26, below baseline. [Details](#)

Influenza-Like Illness (ILI)

Overall, 2.5% of outpatient medical encounters were due to ILI, at baseline. [Details](#)



Severity Indicators

Inpatient

This week, there were no inpatient laboratory positive cases and one inpatient antiviral prescription. No inpatient influenza case reports were identified in DRSi. [Details](#)

Coinfections

No bacterial coinfections were identified among laboratory positive cases during Week 26. [Details](#)

Select Populations

Active Duty and Recruits

In Week 26, there were two laboratory positive cases and six AV prescriptions dispensed to active duty personnel. Among recruits, there were no laboratory positive cases and no AV prescriptions. [Details](#)

NHRC surveillance reports febrile respiratory illness rates were at elevated rates at MCRD San Diego for Week 25. [Details](#)

Children

No influenza positive laboratory cases or AV prescriptions were identified among children. [Details](#)

Active Duty Vaccination Rates

Navy: 95.3%
Marine Corps: 97.3%
US Fleet Forces: 99.9%

[View Table](#)

Data source: MRRS, current as of 05 July 2016.

Prepared by the EpiData Center ([email](#); [web](#))





Influenza Activity and Surveillance

Overall Burden


The estimated burden of influenza across the DON combines three major sources of data: certified laboratory results, antiviral pharmacy transactions, and medical encounters with influenza-specific diagnoses.

- During Week 26, there were 10 DON cases identified in one or more data sources; pharmacy captured the highest proportion of cases (60.0). All cases were only identified in one source.
- Since Week 40, there have been 6,870 DON cases identified in at least one of the three data sources.





Laboratory Cases

- Two laboratory positive influenza cases were identified during Week 26 (one Type A, and one Type B), below baseline.
 - Both cases were identified at NH Jacksonville.
- Since Week 40, 2,461 laboratory positive cases were identified among DON beneficiaries. Top three facilities thus far: NMC San Diego (455), NH Jacksonville (244), NH Camp Pendleton (174).



Specimen Positivity

- 1.4% of all influenza specimens tested during Week 26 were positive, below the percentage for the same time last season (7.1%).
- When grouped by parent facility, three locations (10.7%) tested more than ten specimens. None of these facilities (NH Camp Pendleton, NMC San Diego or NH Camp Lejeune) had any positive specimens.




| Test Types among Positive Influenza Specimens, n (%) | | | | |
|--|-------------|------------|------------|-------|
| | Rapid | Culture | PCR | Total |
| Week 24 | 3 (50.0) | 2 (33.3) | 1 (16.7) | 6 |
| Week 25 | 3 (100.0) | 0(0.0) | 0(0.0) | 3 |
| Week 26 | 2(100.0) | 0(0.0) | 0(0.0) | 2 |
| Season | 1618 (59.9) | 310 (11.5) | 772 (28.6) | 2,700 |

Antiviral Prescriptions

- Six antiviral prescriptions (all oseltamivir) were dispensed during Week 26. AV prescriptions were below baseline.
- This week NMC San Diego had 2 AV prescriptions, while 4 other facilities had one prescription each.
- Since Week 40, the majority (99.0%) of prescriptions were for oseltamivir.

| Antiviral Medications Dispensed to DON Beneficiaries, n (%) | | | | | |
|---|------------|--------------|-------------|-----------|-------|
| | Amantadine | Oseltamivir | Rimantadine | Zanamivir | Total |
| Week 26 | 0(0.0) | 6(100.0) | 0 (0.0) | 0 (0.0) | 6 |
| Season | 42(1.0) | 4,217 (99.0) | 0 (0.0) | 0 (0.0) | 4,259 |




[< Back to Key Findings](#)



Syndromic Surveillance

Influenza-Like Illness (ILI)

- The percent of medical encounters that included an ILI diagnosis during Week 25 (lagged due to data availability):
 - 2.5% of outpatient encounters (at baseline)
 - 8.6% of ER admissions (below baseline)
- When grouped by parent facility, 9 DON facilities (32.1%) experienced an increase in the proportion of outpatient ILI visits during Week 25 compared to the previous week. Two facilities experienced an increase above 25%: NH Twentynine Palms and Walter Reed National Military Medical Center.



Severity Indicators

Inpatient Laboratory



- No influenza positive laboratory cases were identified in the inpatient setting during Week 26.

Inpatient Pharmacy

- One influenza AV was prescribed in the inpatient setting during Week 26 (16.7% of all antivirals prescribed), below baseline (26.0%).
- NMC San Diego dispensed the AV to an active duty service member.

Influenza-Associated Hospitalization Reports

- No influenza cases were reported to DRSi during Week 26.



Bacterial Coinfections

- No coinfections were identified during Week 26.
- The cumulative coinfection case count is above baseline for the season.

| Proportion Bacterial Coinfections by Respiratory Source and Percent of Laboratory Positive Cases with a Bacterial Coinfections since Week 40, 2015-2016 Season | | | | |
|--|---|-------------------|-----------------|--|
| | Coinfections by Respiratory Source, n (%) | | | Lab Cases with Bacterial Coinfection (%) |
| | Upper Respiratory | Lower Respiratory | Non-Respiratory | |
| Current Season (n=106) | 44 (41.5) | 13 (12.3) | 49(46.2) | 4.3 |
| Cumulative Baseline (n=105.7) | 39.2 (37.1) | 11 (10.4) | 55.5 (52.5) | 3.9 |

* Cumulative baseline calculated as a weighted average over three years and may not represent whole numbers.


[< Back to Key Findings](#)



Select Populations

Active Duty

- Two laboratory positive influenza cases were identified among active duty DON service members (Navy) during Week 26 (Type A). Both cases were identified at NH Jacksonville.
- Three active duty service members (all Navy) were dispensed AVs (all oseltamivir) during Week 26.



| Status | Immunity Status | LAIV | IV | LAIV & IV | None | Total | Percent |
|--------------|------------------------|-----------|------------|-----------|-----------|------------|---------|
| Active Duty | Vaccinated; immune | 82 | 164 | 5 | - | 251 | 80.4% |
| | Vaccinated; not immune | 7 | 13 | - | - | 20 | 6.4% |
| | No vaccination record | - | - | - | 41 | 41 | 13.1% |
| Total | | 89 | 177 | 5 | 41 | 312 | - |
| Recruit | Vaccinated; immune | 22 | 25 | - | - | 47 | 45.2% |
| | Vaccinated; not immune | 18 | 10 | - | - | 28 | 26.9% |
| | No vaccination record | - | - | - | 29 | 29 | 27.9% |
| Total | | 40 | 35 | - | 29 | 104 | - |

LAIV-live attenuated influenza vaccine (intranasal), IV-inactivated influenza vaccine (injection)



Recruits

- No laboratory positive influenza cases were identified among recruits during Week 26.
- No AVs were dispensed to recruits during Week 26.

| Number of DON Active Duty and Recruit Cases since Week 40, 2015-2016 Season | | | | | |
|---|-------------|--------------|----------|--------------|-------|
| Case Type | Active Duty | | Recruits | | Total |
| | Navy | Marine Corps | Navy | Marine Corps | |
| Laboratory Positive | 229 | 83 | 21 | 83 | 416 |
| AV Prescriptions | 539 | 189 | 9 | 118 | 855 |

Children

- No positive laboratory cases were identified among children during Week 26.
- No AV prescriptions were dispensed to children during Week 26.



In the News

- Flu activity is winding down with only two states reporting wide spread flu activity. [Details](#)
- The CDC's Advisory Committee on Immunization Practices (ACIP) is not recommending the "nasal spray" influenza vaccine for the 2016-2017 flu season. The recommendation follows a study showing the nasal spray vaccine to have no protective benefits. The nasal spray vaccine was projected to make up about 8% of the vaccine supply for the 2016-2017 season, potentially affecting providers who have already placed vaccine orders. [Details](#)

[< Back to Key Findings](#)

